New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
08:16 EDTIMGNImmunoGen announces initial safety and response findings for SAR650984
ImmunoGen announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy. SAR650984 was initially developed by ImmunoGen with the Companyís target evaluation and antibody development expertise and was licensed to Sanofi as part of a broader collaboration between the companies. The findings reported are from a Phase I trial designed to determine the maximum tolerated dose and maximum administered dose of SAR650984, which is identified by administering increasing doses of the compound to new cohorts of patients until dose-limiting toxicity is reported. Secondary objectives of the trial include characterization of the compoundís safety profile, assessing its pharmacokinetics, and identifying preliminary evidence of disease response. SAR650984 was found to have a favorable safety profile. The most common treatment emergent adverse events, of any grade, were fatigue, nausea, pyrexia, cough, anemia, and headache. At the time of data cutoff for presentation, the highest dose evaluated was 20 mg/kg given over a two week period and the MTD had not been established. Infusion reactions were reported, and typically occurred during the first dose. These were managed with routine measures, with standard premedications required.
News For IMGN From The Last 14 Days
Check below for free stories on IMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
12:00 EDTIMGNImmunoGen rises 12.9%
ImmunoGen is up 12.9%, or $1.65, to $14.45
10:00 EDTIMGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A10 Networks (ATEN) initiated with a Buy at BofA/Merrill... Actavis (ACT) initiated with a Buy at Sterne Agee... Allergan (AGN) initiated with a Buy at Sterne Agee... Autohome (ATHM) initiated with a Neutral at Credit Suisse... BitAuto (BITA) initiated with an Outperform at Credit Suisse... Centene (CNC) initiated with a Neutral at UBS... Endo International (ENDP) initiated with a Buy at Sterne Agee... FS Investment (FSIC) initiated with an Overweight at Evercore... Hertz (HTZ) initiated with a Buy at Gabelli... Hilton (HLT) initiated with a Hold at Jefferies... Hospira (HSP) initiated with a Neutral at Sterne Agee... ImmunoGen (IMGN) initiated with a Buy at Canaccord... Impax (IPXL) initiated with a Neutral at Sterne Agee... Imperva (IMPV) assumed with a Neutral at Wedbush... Ingredion (INGR) initiated with an Outperform at Credit Suisse... Laredo Petroleum (LPI) initiated with an Outperform at RW Baird... Lpath (LPTN) initiated with a Buy at Canaccord... MediWound (MDWD) initiated with an Outperform at Oppenheimer... Medivation (MDVN) initiated with a Hold at Canaccord... NPS Pharmaceuticals (NPSP) assumed with a Buy at Canaccord... Nimble Storage (NMBL) initiated with a Market Perform at Raymond James... Regeneron (REGN) initiated with a Buy at Canaccord... Salix (SLXP) initiated with a Buy at Sterne Agee... Sibanye Gold (SBGL) initiated with an Outperform at Imperial Capital... Teva (TEVA) initiated with a Neutral at Sterne Agee... Wipro (WIT) assumed with a Hold at Jefferies.
10:00 EDTIMGNImmunoGen rises 9%
ImmunoGen is up 9%, or $1.15, to $13.95
05:19 EDTIMGNImmunoGen initiated with a Buy at Canaccord
Subscribe for More Information
April 9, 2014
10:16 EDTIMGNHigh option volume stocks: IMGN GTN RDA AXAS CTSH
April 8, 2014
16:25 EDTIMGNInitial findings show new dosing approach for IMGN853 achieves objective
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use